Clinical Trial Update: Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing 0.5 mg daily dutasteride to placebo in men receiving androgen deprivation therapy for prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Dutasteride (Avodart) (dutasteride)

Snippet

Sponsor: Canadian Urology Research Consortium | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED